ArticleBMC medical imaging2026
CT and MRI findings of intraductal tubulopapillary neoplasm of the pancreas.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the computed tomography (CT) and magnetic resonance imaging (MRI) characteristics of intraductal tubulopapillary neoplasms (ITPNs) of the pancreas and to correlate these features with clinicopathologic findings for improved preoperative recognition.
methodsEight patients were retrospectively analyzed with surgically confirmed ITPNs treated between October 2015 and June 2024 (median age, 68 years; range, 47–76). All patients underwent preoperative CT, and six underwent MRI. Imaging features, including location, size, morphology, margins, imaging composition, and pancreatic duct dilatation, were assessed. Characteristic signs, such as the “two-tone duct sign” and “cork-of-wine-bottle sign,” were evaluated. Quantitative analysis included unenhanced and peak-enhanced CT attenuation, enhancement amplitude, and apparent diffusion coefficient (ADC) values, compared with adjacent normal pancreatic parenchyma.
resultsLesions predominantly involved the pancreatic head (75%) and were irregular or lobulated in 75% of cases. Ill-defined margins were observed in 75%, and solid–cystic lesion in 25%. Main pancreatic duct dilatation was present in 75% of patients. The “two-tone duct sign” and “cork-of-wine-bottle sign” were detected in 25% and 12.5% of cases, respectively. Quantitative analysis revealed significantly lower enhancement amplitude in ITPNs compared with normal pancreas (35.00 ± 10.58 HU vs. 53.50 ± 11.64 HU, P = 0.03) and a trend toward lower ADC values (1.143 ± 0.312 × 10⁻³ mm²/s vs. 1.372 ± 0.287 × 10⁻³ mm²/s, P = 0.15).
conclusionITPNs typically appear as intraductal, poorly enhancing lesions with irregular morphology and frequent pancreatic duct dilatation. Characteristic signs and quantitative imaging parameters can facilitate preoperative recognition, improve diagnostic accuracy, and guide surgical planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.